Navigation Links
Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
Date:12/16/2008

NEW YORK, LONDON and HAMILTON, Bermuda, Dec. 16 /PRNewswire/ --Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") announced today that the databases have been locked and preliminary analyses completed on the two double-blinded studies of XERECEPT(R) (corticorelin acetate), as a treatment for peritumoral brain edema, as well as an initial database lock on the open-label study of XERECEPT's long-term safety and efficacy.

The results of these studies are the subject of several abstract submissions for the American Society of Clinical Oncology (ASCO) annual meeting in May 2009, as well as the American Association of Cancer Research annual meeting (AACR) in April 2009. In conformance with the requirements of both ASCO and AACR, XERECEPT(R) datawill be published only after presentation at these meetings.

Celtic Pharma has also retained a top-tier investment bank to serve as its financial advisor in the planned sale in 2009 of Neutron Holdings Limited and its geographical subsidiaries who are the owners of the worldwide commercial rights to XERECEPT(R).

"We believe that the trial data we now have in hand indicate the efficacy and long term safety of Xerecept as a treatment for cerebral edema associated with primary and metastatic brain tumors, permitting substantial reductions or elimination of cortico-steroid dosing in this patient population, and that Xerecept has the potential to become part of the generally accepted standard of care for these patients." said Stephen Evans-Freke, Managing General Partner of Celtic Pharma. "We believe we have built substantial value in Xerecept(R) and we look forward to achieving superior returns for our investors through the sale of this important program in 2009." said John Mayo, co-Managing General Partner of Celtic Pharma.

About Celtic Pharmaceutical Holdings L.P.

Celtic Pharmaceutical
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. Pharmasset Reports Fiscal Year End 2008 Financial Results
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
8. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
9. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
10. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
11. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/s9qx9j/asia_pacific_open ) ... Open System MRI Market - Growth, Trends And ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the fastest growing market for Open System MRI. ... replacing CT because of its higher sensitivity and ...
(Date:5/27/2015)... , May 27, 2015  With all the daily ... services they provide to keep patients healthy should be ... effect of the Affordable Care Act continues to affect ... payer partners, making it more important than ever that ... with those they contract with for patient care. ...
(Date:5/27/2015)... May 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ... Pacific Mammography Market - Growth, Trends And Forecasts (2014 ... Mammography is a detailed type of imaging that ... mammography exam, called a mammogram, is used to support ... in women. An x-ray (radiograph) is a noninvasive medical ...
Breaking Medicine Technology:Asia Pacific Open System MRI Market Trends and Forecasts 2015-2019 2Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2
... 2011 Amgen (NASDAQ: AMGN ) will present ... 2011 at the Four Seasons Hotel, Boston, Mass., beginning at ... Relations at Amgen, will present. Live audio of the presentation ... www.amgen.com , under Investors. About ...
... 2011 Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... September: KeyBanc Capital Markets 2011 Basic ... the InterContinental, Boston, MA, presenting at 9:00 AM (Eastern). ... 14, at the Grand Hyatt, New York, NY, presenting ...
Cached Medicine Technology:Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences 2
(Date:5/27/2015)... Diego, CA (PRWEB) May 27, 2015 ... and teleradiology services, is pleased to introduce Mr. Chris ... Mr. Hafey has a proven track record of leading ... healthcare information technology domain. He most recently served as ... previously held the role of Chief Architect for Vital ...
(Date:5/27/2015)... As the U.S. Supreme Court considers ... under the Affordable Care Act (ACA), an investigation by ... the RAND Corporation and Express Scripts provides an unprecedented ... initial enrollees. , The analysis is published online ... will also appear in the journal’s June issue. , ...
(Date:5/27/2015)... The BBB Code of Business Practices represents ... customer trust and confidence in business. The Code is ... that summarize important elements of creating and maintaining trust ... accreditation by BBB. Businesses based in the United States ... procedures will be accredited by BBB. , To be ...
(Date:5/27/2015)... New York, New York (PRWEB) May 27, 2015 ... http://www.risperdallawsuit2014.com/ ) filed on behalf of individuals ... other complications related to the use of the ... mass tort litigation currently underway in Pennsylvania’s Philadelphia ... the litigation is proceeding with its bellwether trial ...
(Date:5/27/2015)... While hair transplantation has been used ... pilot study conducted by a physician member of the ... hair follicle grafting can help treat patients with non-healing ... by ISHRS, which offers research grants for the purpose ... , In the past decade, numerous scientific studies have ...
Breaking Medicine News(10 mins):Health News:StatRad Introduces Mr. Chris E. Hafey as Chief Technology Officer, and the Release of its Advanced Pure HTML5 DICOM Image Uploader 2Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 2Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 3Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 4Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3
... redefine traditional notions of aging ... through friendship and fun, FULLERTON, Calif., April 25 ... invisibility. Thanks,to the Red Hat Society (RHS), founded 10 years ago today, ... few friends who donned,red hats and purple outfits in the spirit of ...
... April 24 Amneal Pharmaceuticals, LLC is,pleased to ... for,Amneal,s wholly-owned subsidiary, Amneal Pharmaceuticals of New York, ... Interpharm. The,acquisition includes Interpharm,s facilities on Long Island, ... ANDA,s, technology and,processes., Amneal will use its ...
... at best cost, study says , , THURSDAY, April 24 ... patients in the United States are being referred for ... to physicians who refer patients to their own facilities ... For the study, Dr. Jean M. Mitchell, a professor ...
... difference in survival when compared to expensive lab tests ... switching to a second-line series of drugs for HIV/AIDS ... made on the basis of sophisticated and expensive lab ... is only slightly affected if these decisions are based ...
... Coalition for 21st,Century Medicine (http://www.twentyfirstcenturymedicine.org ), ... innovative diagnostic technology,companies, clinical laboratories, venture capitalists, ... on the passage of the Genetic,Information Nondiscrimination ... morning., The House of Representatives passed ...
... $225,000, CHICAGO, April 24 Many people think ... often grossly,underestimate their future health care costs. Many also ... Medicare and their employers during their,golden years. However, this ... offering retiree health benefits is steadily declining and the,financial ...
Cached Medicine News:Health News:Hats Off to the Red Hat Society, Which Turns 10 Today 2Health News:Hats Off to the Red Hat Society, Which Turns 10 Today 3Health News:Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings 2Health News:Increase in Diagnostic Imaging Fueled by Self-Referring Doctors 2Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 2Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 3Health News:Coalition for 21st Century Medicine Congratulates U.S. Senate on Passage of Genetic Information Nondiscrimination Act 2Health News:Health Insurance a Key Component in Financial Planning 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
Medicine Products: